Weight, BSA, Toxicity, and Efficacy of Tyrosine Kinase Inhibitors for ALK-Mutated NSCLC
Higher weight and larger BSA at the start of ALK TKI treatment were associated with higher likelihood of toxicity, leading to more DRs and TIs-particularly in males and patients receiving alectinib and lorlatinib. However, weight and BSA were not associated with treatment outcomes.
Authors
- Natasha B. Leighl (ORCID: https://orcid.org/0000-0002-3249-4602)
- Catherine Brown (ORCID: https://orcid.org/0000-0002-9394-8516)
- Beatriz Jimenez Munarriz
- Katrina Hueniken (ORCID: https://orcid.org/0000-0003-1376-8046)
- Adrian G. Sacher (ORCID: https://orcid.org/0000-0001-7865-2701)
- Lawson Eng (ORCID: https://orcid.org/0000-0002-4816-8385)
- Luna Jia Zhan (ORCID: https://orcid.org/0000-0003-2534-7230)
- Frances A. Shepherd (ORCID: https://orcid.org/0000-0002-3610-3533)
- Sameena Khan
- Geoffrey Liu (ORCID: https://orcid.org/0000-0002-2603-7296)
- Devalben Patel
- Penelope A. Bradbury
- Shirley Tam
Institutions
- University of Toronto (CA)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1016/j.jtocrr.2025.100918
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 1.52